Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)

SHE:301089 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	410.33	421.65	831.98	777.81	500.26	513.09
Other Revenue	0.04	0.04	3.53	6.91	2.22	14.86
Revenue	410.37	421.69	835.51	784.72	502.48	527.94
Revenue Growth (YoY)	4.46%	-49.53%	6.47%	56.17%	-4.82%	36.79%
Cost of Revenue	296.79	309.52	365.37	329.64	314.12	304.54
Gross Profit	113.57	112.17	470.14	455.08	188.36	223.4
Selling, General & Admin	104.62	101.32	101.65	107.5	75.61	57.33
Research & Development	40.93	40.05	51.25	31.02	20.97	18.82
Other Operating Expenses	9.34	7.87	13.02	11.77	6.79	6.15
Operating Expenses	160.97	153.32	170.4	147.28	104.45	82.46
Operating Income	-47.4	-41.15	299.74	307.8	83.92	140.94
Interest Expense	-0.09	-0.05	-0.34	-3.38	-9.13	-13.87
Interest & Investment Income	2.5	3.31	9.86	10.64	2.41	2.47
Currency Exchange Gain (Loss)	1.03	1.03	0.68	1.5	-1.19	-1.23
Other Non Operating Income (Expenses)	-0.36	-0.21	-0.27	1.83	-1.82	-0.48
EBT Excluding Unusual Items	-44.33	-37.07	309.66	318.39	74.19	127.83
Gain (Loss) on Sale of Investments	1.94	0.88	0.55	0.16	0.62	-
Gain (Loss) on Sale of Assets	-0	-0.01	-	0.03	-	-0.37
Asset Writedown	-1.42	-1.42	-4.22	-1.03	-0.3	-
Other Unusual Items	9.65	9.88	10.54	7.73	3.53	7.98
Pretax Income	-34.15	-27.73	316.53	325.27	78.04	135.44
Income Tax Expense	-8.63	-7.85	73.46	38.73	12.33	22.64
Earnings From Continuing Operations	-25.52	-19.88	243.07	286.54	65.71	112.8
Net Income	-25.52	-19.88	243.07	286.54	65.71	112.8
Net Income to Common	-25.52	-19.88	243.07	286.54	65.71	112.8
Net Income Growth	-	-	-15.17%	336.05%	-41.75%	84.16%
Shares Outstanding (Basic)	128	124	126	126	100	95
Shares Outstanding (Diluted)	128	124	126	126	100	95
Shares Change (YoY)	6.46%	-1.32%	-0.22%	26.78%	5.03%	0.59%
EPS (Basic)	-0.20	-0.16	1.93	2.27	0.66	1.19
EPS (Diluted)	-0.20	-0.16	1.93	2.27	0.66	1.19
EPS Growth	-	-	-14.98%	243.94%	-44.54%	83.08%
Free Cash Flow	-56.62	18.76	-158.27	120.52	-54.53	45.88
Free Cash Flow Per Share	-0.44	0.15	-1.26	0.95	-0.55	0.48
Dividend Per Share	-	-	0.250	0.400	0.100	-
Dividend Growth	-	-	-37.50%	300.00%	-	-
Gross Margin	27.68%	26.60%	56.27%	57.99%	37.49%	42.32%
Operating Margin	-11.55%	-9.76%	35.88%	39.22%	16.70%	26.70%
Profit Margin	-6.22%	-4.71%	29.09%	36.51%	13.08%	21.37%
Free Cash Flow Margin	-13.80%	4.45%	-18.94%	15.36%	-10.85%	8.69%
EBITDA	0.13	6.19	346.33	348.32	114.84	158.33
EBITDA Margin	0.03%	1.47%	41.45%	44.39%	22.85%	29.99%
D&A For EBITDA	47.53	47.34	46.59	40.52	30.92	17.39
EBIT	-47.4	-41.15	299.74	307.8	83.92	140.94
EBIT Margin	-11.55%	-9.76%	35.88%	39.22%	16.70%	26.70%
Effective Tax Rate	-	-	23.21%	11.91%	15.80%	16.72%
Revenue as Reported	410.37	421.69	835.51	784.72	502.48	527.94
Advertising Expenses	-	4.71	1.81	1.15	0.66	0.81

Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.